en · de · es · pt
cjc-1295-notes.peptides3081.com › Faq › Persistence, Stability And Measurement — Quick Reference

Persistence, Stability And Measurement — Quick Reference

By Editorial Desk · published 2026-04-13 · last reviewed 2026-05-26 · Faq

Everything below concerns GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-05-26. Numbers and descriptions here follow the published literature rather than marketing material.

Persistence, Stability and Measurement

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.

Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.

Identity and Naming History

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.

Cjc-1295 at a glance

PropertyValueNotes
Molecular massApproximately 3.4 to 3.6 kDaDepends on whether the affinity complex is attached
AppearanceWhite to off-white lyophilized powderFreeze-dried solid, often in a sealed vial
SolubilitySoluble in water and aqueous buffersDissolution rate varies with pH and buffer salt
Typical storageBelow minus 20 degrees Celsius, dry and darkDissolved material is usually kept cold and used promptly
Common analytical methodsReversed-phase HPLC and mass spectrometryPeptide mapping and amino acid analysis add sequence detail

Compound Identity and Development History

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

Related pages on this site

Analytical Measurement And Stability

Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.

Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.

Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.

CJC-1295 Background and Mechanism

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.

The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

Supporting material

The influence of Nasser's Arab nationalism over the RCC was immediately apparent. The administration was instantly recognized by the neighbouring Arab nationalist regimes in Egypt, Syria, Iraq, and Sudan, with Egypt sending experts to aid the inexperienced RCC. Gaddafi propounded pan-Arab ideas, proclaiming the need for a single Arab state stretching across North Africa and the Middle East. In December 1969, Libya signed the Tripoli Charter alongside Egypt and Sudan. This established the Arab Revolutionary Front, a pan-national union designed as a first step towards the eventual political unification of the three nations. In 1970 Syria declared its intention to join. Nasser died unexpectedly in September 1970, with Gaddafi playing a prominent role at his funeral. Nasser was succeeded by Anwar Sadat, who replaced the idea of a unified state with a political federation, implemented in April 1971; in doing so, Egypt, Syria, and Sudan received large grants of Libyan oil money. In July 1971, Gaddafi sided with Sadat against the Soviet Union in the 1971 Sudanese coup d'état and dispatched Libyan fighter jets to force down a British Overseas Airways Corporation jetliner carrying the leading coup plotters, Farouk Osman Hamadallah and Babikir al-Nour. They were extradited back to Khartoum, where they were promptly executed by Sudanese leader Jaafar Nimeiry. In February 1972, Gaddafi and Sadat signed an unofficial charter of merger, but it was never implemented because relations broke down the next year.

== Causes == When diving, the pressure differences which cause the barotrauma are changes in hydrostatic pressure. There are two components to the surrounding pressure acting on the diver: the atmospheric pressure and the water pressure. A descent of 10 metres (33 feet) in water increases the ambient pressure by an amount approximately equal to the pressure of the atmosphere at sea level. So, a descent from the surface to 10 metres (33 feet) underwater results in a doubling of the pressure on the diver. This pressure change will reduce the volume of a flexible gas-filled space by half. Boyle's law describes the relationship between the volume of the gas space and the pressure in the gas. Barotraumas of descent, also known as compression barotrauma, and squeezes, are caused by preventing the free change of volume of the gas in a closed space in contact with the diver, resulting in a pressure difference between the tissues and the gas space, and the unbalanced force due to this pressure difference causes deformation of the tissues resulting in cell rupture. Barotraumas of ascent, also called decompression barotrauma, are also caused when the free change of volume of the gas in a closed space in contact with the diver is prevented. In this case the pressure difference causes a resultant tension in the surrounding tissues which exceeds their tensile strength. Patients undergoing hyperbaric oxygen therapy must equalize their ears to avoid barotrauma. High risk of otic barotrauma is associated with unconscious patients.

== Occurrence == It is also produced by Cordyceps kyusyuensis (a close relative of C. militaris), but not by other insect pathogenic fungi such as C. bassiana, C. confragosa, C. takaomontana, Isaria fumosorosea, M. robertsii, and M. rileyi. Evidence for cordycepin in Ophiocordyceps sinensis (syn. Cordyceps sinensis) has been mixed, and its presence in this species was long considered controversial. More recent analyses using authenticated material and sensitive methods have detected low but measurable amounts: an HPLC–MS/MS study quantified cordycepin at 0.0076–0.029% (w/w) in authenticated wild material, a PLOS ONE comparison reported cordycepin in both cultivated and wild forms (higher on average in cultivated), and independent HPLC work found ~3 ppm in both wild and in‑vitro‑cultured O. sinensis mycelium. Overall, reported detection appears to be sample‑ and method‑dependent. It is also produced by Samsoniella hepiali (fungus identity confirmed by 18S rRNA) and Aspergillus nidulans Y176-2.

=== Variation among organisms === Organisms vary in their ability to take up foreign dsRNA and use it in the RNAi pathway. The effects of RNAi can be both systemic and heritable in plants and C. elegans, although not in Drosophila or mammals. In plants, RNAi is thought to propagate by the transfer of siRNAs between cells through plasmodesmata (channels in the cell walls that enable communication and transport). Heritability comes from methylation of promoters targeted by RNAi; the new methylation pattern is copied in each new generation of the cell. A broad general distinction between plants and animals lies in the targeting of endogenously produced miRNAs; in plants, miRNAs are usually perfectly or nearly perfectly complementary to their target genes and induce direct mRNA cleavage by RISC, while animals' miRNAs tend to be more divergent in sequence and induce translational repression. This translational effect may be produced by inhibiting the interactions of translation initiation factors with the mRNA's polyadenine tail. Some eukaryotic protozoa such as Leishmania major and Trypanosoma cruzi lack the RNAi pathway entirely. Most or all of the components are also missing in some fungi, most notably the model organism Saccharomyces cerevisiae. The presence of RNAi in other budding yeast species such as Saccharomyces castellii and Candida albicans, further demonstrates that inducing two RNAi-related proteins from S. castellii facilitates RNAi in S. cerevisiae.

Sources: en.wikipedia.org

Notes from published material

=== Section Praegnans === Cyclopia alopecuroides A.L. Schutte Cyclopia aurescens Kies Cyclopia bolusii Hofmeyr & E. Phillips Cyclopia bowieana Harv. Cyclopia glabra (Hofmeyr & E. Phillips) A.L. Schutte Cyclopia meyeriana Walp.

=== Weaning === During weaning, decreased prolactin, missing mechanical stimulation (baby suckling), and changes in osmotic balance caused by milk stasis and leaking of tight junctions cause cessation of milk production. It is the (passive) process of a child or animal ceasing to be dependent on the mother for nourishment. In some species there is complete or partial involution of alveolar structures after weaning, in humans there is only partial involution and the level of involution in humans appears to be highly individual. The glands in the breast do secrete fluid also in nonlactating women. In some other species (such as cows), all alveoli and secretory duct structures collapse by programmed cell death (apoptosis) and autophagy for lack of growth promoting factors either from the ECM or circulating hormones. At the same time, apoptosis of blood capillary endothelial cells speeds up the regression of lactation ductal beds. Shrinkage of the mammary duct tree and ECM remodeling by various proteinase is under the control of somatostatin and other growth inhibiting hormones and local factors. This major structural change leads loose fat tissue to fill the empty space afterward. But a functional lactiferous duct tree can be formed again when a female is pregnant again.

IQSEC2: encodes an exchange factor for the Arf family of small GTP binding proteins, involved in the formation of secretory vesicles. TM4SF2: is a member of the 4 transmembrane domains family of proteins (tetraspanins, see TSPAN7). This gene is also associated with neuropsychiatric diseases such as Huntington's chorea. AP1S2: AP-1 complex subunit sigma-2. Adaptor protein complex 1 is found on the cytoplasmic face of vesicles located at the Golgi complex, where it mediates both the recruitment of clathrin to the membrane and the recognition of sorting signals within the cytosolic tails of transmembrane receptors. ACSL4: Long-chain-fatty-acid—CoA ligase 4 is an enzyme of the long-chain fatty-acid-coenzyme A ligase family. It converts free long-chain fatty acids into fatty acyl-CoA esters, and thereby play a key role in lipid biosynthesis and fatty acid degradation. This isozyme preferentially utilizes arachidonate as substrate. ZNF41: Zinc finger protein 41 is a likely zinc finger family transcription factor. DLG3: Disks large homolog 3, also named neuroendocrine-DLG or synapse-associated protein 102 (SAP-102). DLG3 is a member of the membrane-associated guanylate kinase (MAGUK) superfamily. FTSJ1: Transfert RNA methyltransferase 1 is a member of the S-adenosylmethionine-binding protein family. This nucleolar protein is involved in the processing and modification of tRNA. GDI1: RabGDI alpha makes a complex with geranylgeranylated small GTP-binding proteins of the Rab family and keeps them in the cytosol.

Sources: en.wikipedia.org

Background from the literature

=== Withdrawal === The magnitude and speed of dose reduction in corticosteroid withdrawal should be determined on a case-by-case basis, taking into consideration the underlying condition being treated, and individual patient factors such as the likelihood of relapse and the duration of corticosteroid treatment. Gradual withdrawal of systemic corticosteroids should be considered in those whose disease is unlikely to relapse and have:

The city currently has a large number of rail and road work sites. Although this activity has increased as a result of the 2006 Winter Olympics, parts of it had long been planned. Some of the work sites deal with general roadworks to improve traffic flow, such as underpasses and flyovers, but two projects are of major importance and will radically change the shape of the city. One is the Spina Centrale ('Central Spine') project which includes the doubling of a major railway crossing the city, the Turin-Milan railway locally known as Passante Ferroviario di Torino ('Turin Railway Bypass'). The railroad previously ran in a trench, which will now be covered by a major boulevard running from north to south of Turin, in a central position along the city. Porta Susa, on this section, will become Turin's main station to substitute the terminus of Porta Nuova with a through station. Other important stations are Stura, Rebaudengo, Lingotto and Madonna di Campagna railway stations, though not all of them belong to the layout of the Spina Centrale.

=== 13 February === Thomas Bach, head of the IOC, stood by the offer of allowing Russian and Belarusian athletes to participate under a white or neutral flag for the 2024 Paris Olympics, saying that national governments should not decide who can participate in sports competitions. It was reported that Pakistan had sent some 10,000 Grad rockets to Ukraine in February.

Heparin acts as an anticoagulant, preventing the formation of clots and extension of existing clots within the blood. Heparin itself does not break down clots that have already formed, instead, it prevents clot formation by inhibiting thrombin and other procoagulant serine proteases. Heparin is generally used for anticoagulation for the following conditions:

Sources: en.wikipedia.org

Frequently asked questions

What is the difference between the forms with and without a drug affinity complex?

The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.

Is CJC-1295 the same as MOD GRF 1-29?

In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.

How is the compound identified in a laboratory?

Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.

Is this compound a naturally occurring hormone?

No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.

Network